Home Funding San Francisco based Vineti closes Series C financing

San Francisco based Vineti closes Series C financing

Vineti closes Series C financing

Leading digital platform of record for personalized therapeutics, Vineti closed a US$ 33M extension to its Series C financing on 17 October 2020.

The Series C extension was led by Cardinal Health. Other participants included Marc Benioff and existing Vineti investors, including Canaan Partners, Threshold Ventures (formerly DFJ), Section 32, Casdin Capital, Novartis Pharma AG, McKesson Ventures, and LifeForce Capital, along with other undisclosed entities. Eli Casdin, Chief Investment Officer and Founder of Casdin Capital will join Vineti’s Board of Directors.

In February 2020, Vineti had announced a US$ 35 million Series C financing round. The latest funding brings the total Series C round to $68 million.

The funds raised will be utilized to support further expansion of the company’s Personalized Therapy Management (PTM) platform for personalized and high-value advanced therapies.

About Vineti

Vineti

Founded in 2016, Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of 21st-century medicine. It is the first commercial cloud-based platform to expand patient access to life-saving cell and gene therapies.

Vineti’s platform integrates logistics, manufacturing and clinical data to improve product performance overall. Caregivers and pharmaceutical pioneers are able to help a larger number of patients more effectively and safely, treatments are better understood and improved over time, and most importantly. Vineti also provides an opportunity to provide greater health outcomes-and cures-to patients in need.

Vineti’s enterprise personalized therapy management platform enables the wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, to treat late-stage cancer. Vineti automates patient-centric supply chains for a wide range of advanced therapies in all phases of clinical development and commercial operations. It is currently serving patients, healthcare providers, and researchers in medical centers and manufacturing centers worldwide, on behalf of a growing number of biopharmaceutical partners.

“2020 has driven one key point home – the continued success of advanced therapies relies on standardized, dependable infrastructure. Vineti was built for the purpose of serving personalized medicine. We are now very humbled and honored by the direct support of key industry leaders, including a biopharmaceutical commercialization standard-setter and an enterprise cloud computing pioneer,” said Amy DuRoss, CEO of Vineti.

About Cardinal Health

Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health is a global, integrated healthcare services and products company. It is providing customized solutions for hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide.

Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. It has over 100 years of experience, with around 50,000 employees in 46 countries. 

Read Next article here

We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!

Previous articleThe Space Race of the brave new world
Next articleFLEEP Technologies completed seed funding with €900K investment
Komal writes about the startup ecosystem on VCBay. She is an Economics Hons. graduate from Miranda House, Delhi University, and is passionate about the world of entrepreneurship and finance.

LEAVE A REPLY

Please enter your comment!
Please enter your name here